1. Compliance policy for the quantity of bioavailability and bioequivalence samples retained under 21 CFR 320.38(c) Publication: [Silver Spring, MD] : Center for Drug Evaluation and Research, August 2020 Subject(s): Biological AvailabilityTherapeutic EquivalencyBiopharmaceuticsUnited StatesUnited States. Department of Health and Human Services.United States. Food and Drug Administration.
